Online Marketing Firm Boosts Status with Reputation Platform Deal, Earns 221% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

U.S. stocks rose today as renewed AI optimism, easing trade tensions, and growing expectations for Fed rate cuts boosted investor confidence and pushed the S&P 500 and Nasdaq to record highs.

Netflix (NASDAQ: NFLX) is stepping beyond the screen with the launch of Netflix House, a network of immersive, physical entertainment venues.

The first two locations, Philadelphia’s King of Prussia Mall and Dallas’ Galleria are scheduled to open in late 2025, with a third planned for Las Vegas in 2027.

Each venue will span over 100,000 square feet, featuring interactive experiences based on hit series such as Stranger Things, Squid Game, Wednesday, and One Piece, along with themed dining options under “Netflix Bites.”

This isn’t Netflix’s first experiment with physical activations, but it marks the company’s most ambitious move into year-round, revenue-generating real-world experiences.

While streaming remains the financial core, this new vertical represents a potential long-term growth lever by monetizing Netflix’s IP beyond the screen through tickets, merchandise, and food sales.

From an investor perspective, Netflix House could boost brand loyalty, attract new audiences, and provide a non-subscription revenue stream.

As the streaming race intensifies, Netflix appears to be focusing on building franchises that can extend into experiential territory, similar to Disney’s multi-platform model.

For those weighing an entry into Netflix, the bigger question is scale. Will these venues deliver meaningful revenue, or are they brand plays?

Execution and margins will matter, but the ambition here is clear. Netflix isn’t just testing new formats.

It’s betting that fans will pay to step inside the stories they love, and that could reshape how the company grows in the decade ahead.

A quiet shift is happening in the financial system — and most investors haven’t noticed.

Starting this July, major banks will be allowed to treat physical gold as cash-equivalent assets. Behind the scenes, many are already taking action.

Meanwhile, millions remain locked into paper assets that continue to swing with volatility.

One respected economist recently said gold is now “the only money banks trust.”

A free Wealth Protection Guide is now available, showing how to legally reposition assets before this shift takes hold — using a method that avoids taxes or penalties.

[Click here to access the guide]

P.S. Every day of delay gives the insiders more ground. The window is closing — act before July hits.

GSK (NYSE: GSK) is facing regulatory heat in the U.S. after it decided to withdraw Flovent HFA, a widely used asthma inhaler for children, from the market earlier this year.

The move, which replaced the brand-name inhaler with a higher-priced authorized generic, has drawn accusations of limiting access for Medicaid patients and evading rebate obligations to the federal program.

The removal of the inhaler has sparked concern among healthcare providers, citing an increase in hospitalizations linked to asthma complications.

GSK now faces formal inquiries demanding documentation on its rationale, financial impact, and internal pricing practices.

For those evaluating GSK’s stock, this probe highlights the company’s U.S. market strategies.

Investors should closely monitor how GSK navigates mounting regulatory pressure, especially as public sentiment shifts on drug pricing and access.

The probe may influence future formulary decisions and could lead to legal or reputational fallout that affects Medicaid and public-sector revenues.

It also raises questions about how GSK balances commercial strategy with ESG risks in key therapeutic areas.

Looking ahead, clarity on how GSK responds to this scrutiny, restoring access, addressing pricing models, or absorbing compliance costs, will matter.

With product access becoming a core concern for investors, GSK’s approach here could significantly impact its valuation and risk profile, extending well beyond Flovent.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

Meta Platforms Inc. (NASDAQ: META) has signed multiple renewable energy agreements totaling more than 1 gigawatt, reinforcing its commitment to powering its data centers with sustainable energy.

The latest deals include 791 megawatts from Invenergy projects in Ohio, Arkansas, and Texas, as well as an additional 360 megawatts from Adapture Renewables' solar farms in Texas.

The power is slated to come online between 2027 and 2028.

These strategic purchases come as Meta ramps up data infrastructure to support growing AI workloads.

Clean energy procurement isn't just about ESG optics; it's fast becoming essential for cost-effective, large-scale data center expansion.

With demand for AI computing soaring, Meta is hedging against future electricity price volatility while aligning with climate-conscious institutional investors.

For those eyeing a long-term position at Meta, the move signals proactive cost management and foresight in infrastructure.

Meta's energy strategy complements its capital-intensive AI pivot, and access to scalable clean power will likely be a competitive edge as regulatory pressure mounts globally.

While the stock may not react sharply to power deals alone, this buildout reinforces Meta's readiness for an AI future that requires significant power.

Investors focused on the intersection of AI and infrastructure should take note.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Locafy Ltd [LCFY] $8.14 (+221.74%)

Locafy surged after announcing a strategic partnership with a major reputation platform and showcasing its AI-powered, location-based marketing tools for online visibility.

Blue Gold Limited [BGL] $62.50 (+210.79%)

Blue Gold soared over 200% on its Nasdaq debut after completing a SPAC merger, gaining investor attention.

Synaptogenix Inc [SNPX] $6.04 (+23.37%)

Synaptogenix surged after rebranding to TAO Synergies and unveiling a bold $10 million investment in TAO tokens, signaling a strategic shift toward blockchain finance.

Lyra Therapeutics Inc [LYRA] $9.11 (-31.91%)

Lyra dropped after announcing a discounted $5 million direct offering with warrants, raising dilution concerns.

Jeffs’ Brands Ltd [JFBR] $6.50 (-21.31%)

Jeffs’ Brands fell after revealing a financing deal for up to $100 million in convertible promissory notes, raising financial risk concerns.

CorMedix Inc [CRMD] $12.50 (-16.44%)

CorMedix declined after pricing a large $85 million public stock offering, triggering investor worries about dilution.

Bitcoin is breaking records. But behind the scenes, a different story is unfolding — one that could catch many investors off guard.

Altcoins are quietly staging their own rally:

→ 100%, 300%, even 1,000%+ moves in some cases
→ Inflow records from major institutions
→ Policy changes accelerating mainstream crypto adoption

A new report reveals how to navigate the current setup — and how to potentially position ahead of what could be a massive rotation into select altcoins.

This updated crypto guide includes:

✔ The signals behind explosive altcoin moves
✔ A simple approach to identifying pre-run momentum
✔ The #1 altcoin setup right now — revealed as a free bonus

Access to this complete research package is just $5.60, but only for the next 48 hours.

[Get instant access here]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.